Objectives The aim of the study was to explore the extent of thrombocytopenia (TCP), anaemia and leucopenia in patients with hepatitis C and evaluate how they impact the management of antiviral therapy, the attainment of sustained virological response (SVR), and some therapy-related adverse events. Materials and methods The Scottish Hepatitis C Clinical Database was used in this retrospective study. The prevalence of TCP, anaemia and leucopenia was evaluated. The impact of the three deficiencies on antiviral therapy management, serious adverse events and SVR attainment was assessed in patients who received therapy. Results The prevalence of TCP, anaemia and leucopenia was 18.5, 0.9 and 0.2% among 4907 treated patients at baseline, increasing to 72, 25.8 and 5.4% during treatment, respectively. Dose reduction occurred in 29.3% of the patients without TCP; this percentage was higher in those with baseline TCP (53%) and in those who acquired it during treatment (35%). Similar results were found for anaemia and leucopenia. Baseline TCP (odds ratio = 0.67, P < 0.001) and baseline anaemia (odds ratio = 0.43, P = 0.03) were identified as risk factors associated with lower SVR rate; acquired TCP and anaemia were not associated with reduced SVR. Conclusion Baseline TCP or anaemia increased the risk of dose cessation. Patients who acquired TCP, anaemia or leucopenia during treatment did not exhibit compromised SVR rates, whereas patients with TCP or anaemia at baseline did. The potential benefit of growth factors in maintaining SVR rate is likely to be confined to those with baseline TCP or anaemia rather than to those who acquire it during therapy, where dose reduction does not appear to reduce the chance of SVR. 
Introduction
Thrombocytopenia (TCP), anaemia and leucopenia can be complications of chronic liver disease and considered indicators of advanced disease. Their causes are multifactorial and include portal hypertension, hypersplenism, decreased thrombopoietin production and virus-induced bone marrow suppression [1] [2] [3] . Furthermore, TCP, anaemia and leucopenia can also be significant side effects during hepatitis C therapy, which involves peginterferon-α and ribavirin, which was the standard of care for hepatitis C until very recently [4, 5] , and with the current high cost of new direct-acting antivirals may remain the mainstay of therapy for many patients for the foreseeable future. For patients with hepatitis C virus (HCV) genotype 1, the addition of protease inhibitors, boceprevir and telaprevir, has been proven to improve efficacy of antiviral therapy (AVT), but further increases the frequency as well as the severity of anaemia [6, 7] . As a result, in some patients with HCV infection, TCP, anaemia and leucopenia prevent initiation of AVT, whereas in others even if they are able to initiate therapy they have to undergo dose reductions and/ or early treatment discontinuation (i.e. dose cessation) to manage these three deficiencies. Such suboptimal therapy has been demonstrated to be associated with a reduced ability to achieve sustained virological response (SVR) [1, 5, 6, [8] [9] [10] . The development and approval for use of second-generation direct-acting antivirals means that some patients have the option of interferon-free regimens, which avoid the cytopenias associated with interferon-α, but the high cost of these regimens means that many patients, in many countries, will continue to be treated with interferon-based regimens.
Limited data exist on the extent of TCP, anaemia and leucopenia among patients with HCV, both before treatment and in response to therapy. Especially for TCP, if there are data they usually refer to normal range definitions of TCP -that is, platelet count less than 150 × 10 9 /lwhich, although a limit of normality, is meaningless in terms of clinical risk of bleeding or indication for therapy reduction or cessation. However, in clinical practice, TCP generally impacts the management of patients with HCV at lower platelet levels and there is lack of data regarding the prevalence of TCP at these clinically meaningful values. In addition, current management of TCP, anaemia and leucopenia in patients who are being treated for HCV is dose reduction of the AVT or even treatment cessation. There is the option to use growth factors to support platelets, leucocytes and erythrocytes, but their current role is not well defined. However, there are limited small-scale data to show how many patients are impacted by this and how such suboptimal AVT impacts treatment successthat is, attainment of SVR.
The objectives of this study were to understand the extent of TCP, anaemia and leucopenia (prevalence) among patients with HCV in a whole country treatment population (Scotland), to evaluate how TCP, anaemia and leucopenia impact the management of AVT, as well as to assess the SVR rates and some other therapy-related adverse events (on-treatment bleeding, hepatic decompensation, sepsis and thromboembolic events) among the patients who received AVT for HCV, doing this for the first time at a national level avoiding the selection biases associated with specialist centres treating more advanced disease.
Materials and methods
The retrospective descriptive database study is based on the National HCV Clinical database held at Health Protection Scotland, which has been collecting data since year 2002 from patients diagnosed with active hepatitis C in 11 Scottish National Health Service board areas running HCV treatment clinics [11] . Patients were defined by a unique combination of forename initial, surname soundex, date of birth and sex. All patients in the database who had a record of a positive PCR test for HCV were initially included. Among the included patients, the haematology test records with missing platelet count, haemoglobin level or white cell count were excluded.
The patients who received AVT were selected to further explore how TCP, anaemia and leucopenia impacted the management of AVT (i.e. treatment dosing), SVR attainment and the onset of serious adverse events. As part of routine clinical practice, blood counts are monitored before treatment, during treatment, at the end of treatment (that would identify dose reductions and dose cessations), and at 6 months after treatment (that would identify SVR). For the patients who were treated twice or more, only the latest treatment was considered. The platelet count, haemoglobin level and white cell count before the initiation of AVT were considered as baseline values. The lowest platelet count, haemoglobin level and white cell count during treatment were considered as nadir values during AVT.
Continuous variables were summarized as median with interquartile range and categorical variables as frequencies with percentages. The prevalence at baseline of TCP, anaemia and leucopenia was determined both in the patients without AVT and in those who received AVT. Baseline refers to the first attendance with TCP, anaemia or leucopenia, defined according to mean laboratory test results within a 3-month window around this first attendance date. Given that in clinical practice TCP generally impacts management at lower platelet levels than the textbook clinical definition -that is, platelet count less than 150 × 10 9 /l -the prevalence of TCP was evaluated in the following ranges of platelet count: (a) 100-150 × 10 9 /l; (b) 75-100 × 10 9 /l; (c) 50-75 × 10 9 /l; (d) 25-50 × 10 9 /l; and (e) up to 25 × 10 9 /l. Anaemia and leucopenia were defined as a single occurrence of haemoglobin level less than 10 g/dl and white cell count less than 1.5 × 10 9 /l, respectively.
Among the patients who received treatment, dose reductions and dose cessations were identified according to different degrees of severity of TCP, anaemia and leucopenia. The impact of TCP, anaemia and leucopenia on serious adverse events during AVT was assessed. SVR rates were also evaluated according to different statuses of TCP, anaemia and leucopenia (i.e. never acquired, acquired at baseline and acquired during AVT), and according to different management strategies for AVT (i.e. optimal dosing, dose reduction alone, dose cessation alone, and both dose reduction and dose cessation).
Logistic regression was used to investigate the impact of baseline characteristics on SVR attainment after the last registered treatment. The age at initiation of AVT was considered a continuous variable, and the baseline albumin level, neutrophil count, alanine aminotransferase (ALT) level, bilirubin level, haemoglobin level and white cell count were all grouped as normal or abnormal according to their respective threshold values. Platelet count at baseline was also grouped as normal and abnormal, using the cut-off value of the clinical definitionthat is, 150 × 10 9 /l. Variables with a P value less than or equal to 0.2 in the univariate logistic regression were included in the multivariate analysis [12] . A multiple imputation procedure was conducted to impute missing baseline data for the multivariate logistic regression. Every model during the model building procedure was fitted to 10 imputed data sets arising from the multiple imputation procedure. The model selection procedure was then carried out using a backward stepwise regression based on the Akaike information criterion (AIC) statistic. The model with the smallest AIC was considered the optimal model. The Hosmer-Lemeshow goodness-of-fit test [12] for logistic regression was carried out to see how well the final model fitted the data. Data handling and statistical analyses were conducted in R (version 3.2.0, http://cran. r-project.org/).
Results

Patients
Overall, there were 18 603 HCV antibody-positive patients in the database. The 4743 patients who had no record of a positive HCV PCR test were excluded. This group is a combination of those who did not attend follow-up or had spontaneous resolution of their HCV infection. Another 3034 patients were also excluded because of missing records of platelet count, haemoglobin level or white cell count. In the final cohort, there were 10 826 patients with chronic HCV infection, of whom 7700 (71%) were male, 10 135 (94%) were of white ethnicity, 4343 (40%) were with HCV genotype 1, 4642 (43%) were with HCV genotype 3, 193 (2%) had HIV coinfection, and 630 (6%) had previous AVT experience. In terms of disease stage, 1629 (15%) had established cirrhosis at baseline. The patients who received AVT were older than those without AVT. The duration of AVT was 24 or 48 weeks for the patients who were treatment naive, and it was not extended for those who had previous AVT experience. The patients with HCV genotype 1 were not likely to proceed to AVT, whereas those with HCV genotype 3 were more likely to respond to interferon. Among the 193 patients with combined infection of HCV and HIV, 86 received HCV AVT: most of them (75 of 86) were treated with peginterferon and ribavirin, seven received combined treatment with peginterferon, ribavirin and telaprevir, three received peginterferon alone, and only one received combined treatment with interferon and ribavirin. The other characteristics among these two groups were similar (details shown in Table 1 ).
Prevalence
The prevalence of TCP (in different ranges), anaemia and leucopenia is shown in Table 2 . There were more patients whose platelet count was below 75 × 10 9 /l in the 'Non-AVT' group than that at baseline in the AVT group, which could be one reason that prevented initiation of AVT for some patients. The prevalence of anaemia in the 'Non-AVT' group [5%, 95% confidence interval (CI): 4.4-5.5%] was also much higher than that at baseline in the AVT group (0.9%, 95% CI: 0.7-1.2%). Among the 4907 treated patients, the prevalence of TCP, anaemia and leucopenia at any point during AVT was much higher at 72% (95% CI: 70.7-73.3%), 25.8% (95% CI: 24.6-27%) and 5.4% (95% CI: 4.7-6%), respectively.
Impact of TCP, anaemia and leucopenia on AVT dosing
The numbers and percentage of patients who received optimal dosing, who underwent dose reduction or dose cessation, according to different statuses of TCP, anaemia and leucopenia are shown in Table 3 . Overall, among the 4907 treated patients, 2338 patients (47.6%) received optimal dosing, 1802 patients (36.7%) underwent dose reduction, and 1367 patients (27.9%) underwent dose cessation. There was evidence that 600 patients underwent both dose reduction and cessation. The detailed percentages are shown in the last column of Table 3 . The patients with TCP (at baseline or acquired during AVT) had higher risk of undergoing dose reduction compared with those who never had TCP (53% at baseline, 35% during AVT, 29.3% for non-TCP). Similar results can be found for anaemia and leucopenia. However, only baseline TCP and baseline anaemia increased the risk of undergoing dose cessation. Table 4 shows the detailed number of patients who underwent dose reduction and/or dose cessation. Among all the 1802 dose reductions, 162 (9%) were associated with TCP, 289 (16%) were associated with anaemia, and only 13 (0.7%) were associated with leucopenia. Among the 1367 dose cessations, 42 (3.1%) were associated with TCP, 29 (2.1%) were associated with anaemia, and only eight (0.6%) were associated with leucopenia. Some reductions or cessations were associated with more than one of the three deficiencies, as the patients could have all three. The patients who had an abnormal platelet count at baseline were more likely to undergo TCP-related dose reduction and or TCP-related dose cessation compared with those who had a normal baseline platelet count (reduction: 24.6 vs. 3.3%; cessation: 10.8 vs. 0.5%). The proportion of patients undergoing anaemia-related dose reduction among the patients who had abnormal haemoglobin level at baseline was around two times higher than that among those with normal haemoglobin level at baseline (30.8 vs. 15.8%). All leucopenia-related reductions and cessations occurred among the patients with a normal white cell count at baseline (reduction: 0.7%; cessation: 0.6%). However, the number of patients with an abnormal haemoglobin level (only 46 patients) or an abnormal white cell count (only 11 patients) at baseline was quite small.
Impact of TCP, anaemia and leucopenia on serious adverse events on therapy
The number of patients who had some serious adverse events recorded in the database (on-treatment bleeding, sepsis, hepatic decompensation and thromboembolic events) on therapy is shown in Table 5 . Overall, the rates were low and not strongly associated with TCP, anaemia or leucopenia, but this may have been confounded by dose alteration. Among the 4907 treated patients, 110 patients (2.2%) had on-treatment bleeding, three (< 0.1%) had sepsis, five (< 0.1%) had hepatic decompensation, and two (< 0.1%) had thromboembolic events. The patients with both TCP and leucopenia had the highest risk of ontreatment bleeding (5.43%). The other three adverse events all occurred in patients with either TCP alone or with both TCP and anaemia.
Impact of TCP, anaemia and leucopenia on SVR attainment
The SVR rates of the patients attained, according to different statuses of TCP, anaemia and leucopenia, are shown in Table 6 . The patients who never had TCP and the patients who acquired TCP during AVT had similar overall SVR rates (55.8 and 55.5%), whereas those who had baseline TCP had a much lower SVR rate of 36.5% (95% CI: 33.4-39.7%). In the 'Non-TCP' group and the 'Acquired TCP during AVT' group, the patients whose dose level was reduced had a similar SVR rate as those who received optimal dosing (70.3 vs. 68.7%; 66.7 vs. 61.4%). Similar results were found for anaemia and leucopenia. However, there were no patients who had baseline leucopenia and underwent dose cessation alone; therefore, the SVR rate in this group was not reported. Moreover, there were only two patients who had baseline leucopenia and received both dose reduction and dose cessation, and one of them achieved SVR, which led to a higher SVR rate of 50% (95% CI: 1.3-98.7%) in this group than in those who never had leucopenia and those who acquired leucopenia during AVT. Clearly the small number makes it impossible to draw any conclusion.
Overall risk factors for SVR attainment
In the univariate analysis (Table 7) , baseline TCP [odds ratio (OR) = 0.46, 95% CI: 0.4-0.53, P < 0.001] and baseline anaemia (OR = 0.25, 95% CI: 0.13-0.51, P < 0.001) were inversely associated with SVR, whereas baseline leucopenia did not significantly reduce the SVR rate (OR = 0.34, 95% CI: 0.09-1.3, P < 0.115). In the multivariate analysis, baseline TCP (OR = 0.67, 95% CI: 0.56-0.81, P < 0.001) and baseline anaemia (OR = 0.43, 95% CI: 0.2-0.92, P = 0.03) were identified as risk factors associated with lower SVR rate. The variables with P values greater than 0.05 (sex and baseline neutrophil) were kept in the final model as they could provide some useful information as well as make the model achieve the smallest value of AIC. A 10-fold Hosmer-Lemeshow goodness-offit test for the final multivariate logistic regression model gave a P value 0.148, which indicated that the model fitted the data well.
Discussion
The study determined the prevalence of TCP, anaemia and leucopenia, both before and during the treatment of HCV, among all the known patients with HCV in a whole country, Scotland. The rate of mild baseline TCP was much higher than the reported rate of cirrhosis. Although there may have been under-ascertainment of cirrhosis due to the removal of a requirement for liver biopsy to qualify for treatment in the later stages of the cohort and limited availability of noninvasive assessment of liver fibrosis, it is unlikely that the rate was as high as the rate of TCP. It is more likely that alcohol and other lifestyle factors may have been having an effect. The much higher prevalence of TCP, anaemia and leucopenia during AVT confirmed unsurprisingly that the three deficiencies were all side effects triggered by interferon-based therapy for hepatitis C. Among the patients who received treatment for HCV, the impact of TCP, anaemia and leucopenia on the management of AVT and on the SVR attainment was also evaluated. TCP, anaemia and leucopenia all increased the risk of undergoing dose reduction. Only baseline TCP and baseline anaemia increased the risk of undergoing dose cessation. Acquirement of TCP, anaemia and leucopenia during AVT did not have significant influence on SVR attainment, whereas the presence of TCP and/or anaemia at baseline significantly reduced the chance of achieving SVR. This can be explained by the higher risk of undergoing dose cessation in the patients with baseline TCP or baseline anaemia, which can directly reduce the likelihood of SVR; however, it is also important that these parameters are surrogate markers of cirrhosis, which is a well-known factor for reduced chance of SVR. The reasons for undergoing dose reduction were complicated. The majority of the reductions were triggered by patient-related clinical side effects during treatment, whereas some reductions were due to blood-test-triggered reductions such as TCP, anaemia or leucopenia, which can be regarded as drug toxicity. The patients who demonstrated some toxicity might have been exposed up to and beyond their optimum dose, and dose reduction brought them to optimum dose, but those without toxicity might not have been exposed to their optimum dose; this may in particular be true of ribavirin and to a less extent interferon. This may be the reason that patients who underwent dose reduction had similar or even slightly higher SVR rate than those who received apparently optimal dosing without dose reduction. In this cohort, there was no documented case of growth factors being used. The structure of the database means that these may not have been well recorded. However, very few patients, if any, received any growth factor support such as erythropoietin, granulocyte colony stimulating factor or eltrombopag. Thus, the vast majority of patient events in this cohort related to TCP, anaemia or leucopenia were managed by dose reduction. It is very clear from our data that those patients who had no TCP, anaemia or leucopenia at baseline but acquired it during therapy were managed with dose reduction and had no reduction in their rate of SVR. This suggests that growth factor support is unnecessary for most patients with acquired TCP, anaemia or leucopenia, and the role of these agents lies in improving baseline abnormalities in the hope that this might improve SVR attainment. The assessment of the role of growth factors according to timing of its use is out of the scope of this study. The coexistence of anaemia seems to increase the risk of sepsis, hepatic decompensation and thromboembolic events among TCP patients. TCP, anaemia, leucopenia, and HCV therapy Wang et al.
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In summary, we have shown in a very large cohort of unselected patients representative of a whole nation the rates of TCP, anaemia and leucopenia in HCV-infected patients and demonstrated what happens to these during interferon-based therapy. Patients having pretreatment TCP, anaemia or leucopenia had increased risk of undergoing dose cessation and a reduced chance of SVR. However, acquiring TCP, anaemia and leucopenia during treatment did not have significant impact on attaining SVR, when managed with dose reduction compared with those who did not need dose reduction. This was achieved in a cohort with very little use of growth factor support before or during treatment. The potential benefit of growth factors in maintaining the SVR rate is likely to be confined to those with baseline TCP or anaemia rather than to those who acquired it during therapy, unless they do not respond to dose reduction. Overall, patients who acquire TCP, anaemia or leucopenia during therapy can be managed first line with dose reduction. If this is successful and avoids dose cessation then there is no reduction in the SVR rate.
